We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





New Molecular Diagnostic Platform Developed Using Gold Nanoparticles Shortens COVID-19 Diagnosis Time

By LabMedica International staff writers
Posted on 24 Jan 2022

Researchers have used gold nanoparticles to develop a new molecular diagnostic platform that considerably reduces the time required for COVID-19 detection. More...

The novel nanotechnology-based platform introduced by researchers at the Chung-Ang University (Seoul, South Korea) could also create a paradigm shift in the field of molecular diagnostics, revolutionizing how we detect infectious diseases and tackle future epidemics.

Early COVID-19 detection and isolation are key for controlling disease transmission and protecting vulnerable populations. The current standard for COVID-19 diagnosis is reverse transcriptase-polymerase chain reaction (RT-PCR), a technique in which viral genes are detected after they undergo multiples cycles of amplification. However, this technique is time-consuming, creating a testing backlog across diagnostic centers and leading to delayed diagnoses. The new nanotechnology-based platform can shorten the time required for COVID-19 diagnosis. Their surface-enhanced Raman scattering (SERS)-PCR detection platform - prepared using gold nanoparticles (AuNPs) in the cavities of Au 'nanodimple' substrates (AuNDSs) - can detect viral genes after only eight cycles of amplification. That is almost one-third of the number required with conventional RT-PCR.

The team had earlier developed a novel detection platform in which high-sensitivity SERS signals are produced by AuNPs uniformly arranged in the cavities of AuNDSs through a technique called DNA hybridization. Based on this previous discovery, the researchers developed the novel SERS-PCR platform for COVID-19 diagnosis. The newly developed SERS-PCR assay uses SERS signals to detect "bridge DNA" - small DNA probes that slowly break down in the presence of target viral genes. Therefore, in samples from patients positive for COVID-19, the concentration of bridge DNA (and therefore the SERS signal) continuously decreases with progressive PCR cycles. In contrast, when SARS-CoV-2 is absent, the SERS signal remains unchanged.

The team tested the effectiveness of their system using two representative target markers of SARS-CoV-2, namely, the envelope protein (E) and RNA-dependent RNA polymerase (RdRp) genes of SARS-CoV-2. While 25 cycles were required for RT-PCR-based detection, the AuNDS-based SERS-PCR platform required only eight cycles, considerably reducing the testing duration. Thus, SERS-PCR could be an important tool in the arsenal against the COVID-19 pandemic as well as revolutionize infectious diseases are detected and future epidemics are tackled.

"Conventional RT-PCR is based on the detection of fluorescence signals, so 3–4 hours are required to detect SARS-CoV-2. This speed is not enough considering how rapidly COVID-19 spreads. We wanted to find a way to cut this time at least by half," said Prof. Jaebum Choo, explaining the motivation behind the study. "Although our results are preliminary, they provide an important proof-of-concept for the validity of SERS-PCR as a diagnostic technique. Our AuNDS-based SERS-PCR technique is a promising new molecular diagnostic platform that can considerably shorten the time required for gene detection compared to conventional RT-PCR techniques. This model can be further expanded by incorporating an automatic sampler to develop a next-generation molecular diagnostic system."

Related Links:
Chung-Ang University 


Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic Hematology Analyzer
DH-800 Series
Gold Member
Collection and Transport System
PurSafe Plus®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The LIAISON NES Group A Strep assay is intended for use on the LIAISON NES POC molecular diagnostics system (Photo courtesy of Diasorin)

Group A Strep Molecular Test Delivers Definitive Results at POC in 15 Minutes

Strep throat is a bacterial infection caused by Group A Streptococcus (GAS). It is a leading bacterial cause of acute pharyngitis, particularly in children and adolescents, and one of the most common reasons... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.